ArticleEBioMedicine2018
Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma.
Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- De novo rates of aProceedings of the National Academy of Sciences of the United States of America · 2025Article
- ADARp150 counteracts whole genome duplication.Nucleic acids research · 2024Article
- Apolipoprotein L1 is a tumor suppressor in clear cell renal cell carcinoma metastasis.Frontiers in oncology · 2024Article
- A-to-I RNA editing by ADAR and its therapeutic applications: From viral infections to cancer immunotherapy.Wiley interdisciplinary reviews. RNA · 2023Review
- Z-flipon variants reveal the many roles of Z-DNA and Z-RNA in health and disease.Life science alliance · 2023Article
- ADAR regulates APOL1 via A-to-I RNA editing by inhibition of MDA5 activation in a paradoxical biological circuit.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- ADAR1 Prevents R-loop Accumulation-Driven ATR Pathway Activation in Ovarian Cancer.Journal of Cancer · 2022Article
- Bioinformatics analysis reveals the competing endogenous RNA (ceRNA) coexpression network in the tumor microenvironment and prognostic biomarkers in soft tissue sarcomas.Bioengineered · 2021Article
- Article
- RNA editing in cancer impacts mRNA abundance in immune response pathways.Genome biology · 2020Article
- Non-Coding RNAs in Lung Tumor Initiation and Progression.International journal of molecular sciences · 2020Review
- Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma.Nature communications · 2019Article
- ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD.Acta neuropathologica · 2019Article
- WidespreadRNA (New York, N.Y.) · 2019Article
- Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma.Genome biology · 2019Article
- ADAR1-mediated RNA-editing of 3'UTRs in breast cancer.Biological research · 2018Article
- Regulatory RNA Editing Sites in Cancer: Prediction and Beyond.EBioMedicine · 2018Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Despite tremendous advances in targeted therapies against lung adenocarcinoma, the majority of patients do not benefit from personalized treatments. A deeper understanding of potential therapeutic targets is crucial to increase the survival of patients. One promising target, ADAR, is amplified in 13% of lung adenocarcinomas and in-vitro studies have demonstrated the potential of its therapeutic inhibition to inhibit tumor growth. ADAR edits millions of adenosines to inosines within the transcriptome, and while previous studies of ADAR in cancer have solely focused on protein-coding edits, >99% of edits occur in non-protein coding regions. Here, we develop a pipeline to discover the regulatory potential of RNA editing sites across the entire transcriptome and apply it to lung adenocarcinoma tumors from The Cancer Genome Atlas. This method predicts that 1413 genes contain regulatory edits, predominantly in non-coding regions. Genes with the largest numbers of regulatory edits are enriched in both apoptotic and innate immune pathways, providing a link between these known functions of ADAR and its role in cancer. We further show that despite a positive association between ADAR RNA expression and apoptotic and immune pathways, ADAR copy number is negatively associated with apoptosis and several immune cell types' signatures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.